227 related articles for article (PubMed ID: 12792789)
1. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
2. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
4. Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells.
Lawrence TS
Cancer Res; 1988 Feb; 48(3):725-30. PubMed ID: 2825982
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
7. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
8. Isolation of two Chinese hamster ovary cell mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides.
Davies SM; Davies SL; Harris AL; Hickson ID
Cancer Res; 1989 Aug; 49(16):4526-30. PubMed ID: 2545343
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
10. Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
Vichi PJ; Tritton TR
Cancer Res; 1993 Nov; 53(21):5237-43. PubMed ID: 8106144
[TBL] [Abstract][Full Text] [Related]
11. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
Deffie AM; Batra JK; Goldenberg GJ
Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693
[TBL] [Abstract][Full Text] [Related]
12. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes.
Dynlacht JR; Wong RS; Albright N; Dewey WC
Cancer Res; 1994 Aug; 54(15):4129-37. PubMed ID: 8033146
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II.
Lee FY; Flannery DJ; Siemann DW
Cancer Res; 1992 Jul; 52(13):3515-20. PubMed ID: 1319822
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Baloch Z; Cohen S; Coffman FD
J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
[TBL] [Abstract][Full Text] [Related]
17. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
[TBL] [Abstract][Full Text] [Related]
18. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
19. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
[TBL] [Abstract][Full Text] [Related]
20. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation.
Kim DS; Woo ER; Chae SW; Ha KC; Lee GH; Hong ST; Kwon DY; Kim MS; Jung YK; Kim HM; Kim HK; Kim HR; Chae HJ
Life Sci; 2007 Jan; 80(4):314-23. PubMed ID: 17034819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]